EQL Pharma AB (publ) (EQL.ST)

Sweden · Healthcare · SEK

Key financials

ROE: 5.14%; 2026 (actual)
ROA: 1.51%; 2026 (actual)
Gross Margin: 37.64%; 2026 (actual)
Net Margin: 2.9%; 2026 (actual)
Total Assets: SEK 850,887.00K; 2026 (actual)
Net Income: SEK 12,538.00K; 2026 (actual)
Valuation: SEK 1,606,410.78K; 2026 (actual)
Stock Price: SEK 54.40; 2026 (actual)

Historical & projected performance

Reported figures and Equlion model projections for the next 5 years.

Metric	2026 (actual)	2027	2028	2029	2030	2031
ROE	5.14%	5.95%	8.27%	7.76%	8.6%	8.72%
ROA	1.51%	1.9%	2.73%	2.65%	3.03%	3.19%
Gross Margin	37.64%	37.64%	37.64%	37.64%	37.64%	37.64%
Sector average	17.71%	17.71%	17.71%	17.71%	17.71%	62.35%
Net Margin	2.9%	3.57%	4.76%	4.2%	4.51%	4.67%

Amounts in SEK (thousands); stock price per share. Values that are missing or fail Equlion's automated data-quality checks are shown as “-”. Stock price and valuation carry no data date: they are the Equlion model's estimate for 2026. Projections are model estimates, not investment advice.

Want the full financial forecast report for EQL Pharma AB (publ)? It covers the balance sheet, income statement and Equlion model projections.

Total Assets	SEK 850,887.00K	SEK 874,722.99K	SEK 914,923.26K	SEK 962,423.67K	SEK 1,012,905.08K	SEK 1,058,640.24K
Sector average	SEK 2,900,240.60K	SEK 3,045,009.79K	SEK 3,280,286.42K	SEK 3,536,407.14K	SEK 3,762,908.71K	SEK 1,806,991.80K

Net Income	SEK 12,538.00K	SEK 16,364.74K	SEK 24,457.94K	SEK 24,860.70K	SEK 29,897.49K	SEK 33,059.62K
Sector average	-SEK 22,027.28K	-SEK 904.69K	-SEK 7,253.84K	-SEK 3,858.45K	-SEK 1,547.00K	-SEK 13,704.11K

Valuation	SEK 1,606,410.78K	SEK 1,645,649.29K	SEK 1,679,283.71K	SEK 1,714,622.59K	SEK 1,747,383.18K	SEK 1,779,408.45K
Sector average	SEK 5,151,301.60K	SEK 5,189,236.02K	SEK 5,317,343.69K	SEK 5,514,329.75K	SEK 5,636,782.17K	SEK 3,179,755.44K

Stock Price	SEK 54.40	SEK 55.73	SEK 56.87	SEK 58.06	SEK 59.17	SEK 60.26
Sector average	SEK 48.04	SEK 48.69	SEK 50.45	SEK 52.13	SEK 53.41	SEK 36.70